Disease-specific mortality occurred in 37/174 (21.3%) patients in the whole MLH1-deficient tumor cohort including 0/2 (0.0%) of LS cases, 1/12 (8.3%) of LLS cases and 36/160 (22.5%) of the patients with MLH1 hypermethylation-linked EC. The gene discussed is MLH1; the disease is neoplasm.